1. Short title This Act may be cited as the Enhancing the Security of the U.S. Pharmaceutical Supply Chain Act of 2020 . 2. Table of contents The table of contents for this Act is as follows: Sec. 1. Short title. Sec. 2. Table of contents. Sec. 3. Identification, development, and procurement of priority medicines. Sec. 4. Priority medicine production credit. Sec. 5. Improving regulatory efficiencies for transfer of drugs. 3. Identification, development, and procurement of priority medicines (a) Priority medicines Title XXVIII of the Public Health Service Act ( 42 U.S.C. 300hh et seq.) is amended by adding at the end the following: 2804. Identification of priority medicines (a) Priority medicines The Secretary shall designate as a priority medicine each covered product that— (1) (A) is necessary for use in a public health emergency declared under section 319; or (B) is at high risk of becoming in short supply; and (2) has a vulnerable global supply chain. (b) Global supply chain vulnerability In determining whether a covered product has a vulnerable global supply chain under subsection (a)(2), the Secretary shall consider— (1) the findings of the National Academies of Sciences, Engineering, and Medicine in the report published pursuant to section 4111 of the CARES Act ( Public Law 116–136 ); (2) the number of manufacturers of each covered product; (3) the manufacturing locations, and amount produced, of each covered product; (4) the history of the importation of each priority medicine; and (5) the probability of the imposition of duties on the importation of each covered product. (c) Consultation In carrying out subsection (a), the Secretary shall consult with the Public Health Emergency Medical Countermeasures Enterprise established under section 2811–1. (d) Publication of list The Secretary shall— (1) not later than 180 days after the date of enactment of this section, publish a preliminary list of priority medicines; (2) provide an opportunity for public comment on such preliminary list